Yusuf ÇEKİCİ, Salih KILIÇ, Mehmet KÜÇÜKOSMANOĞLU, Meral KAYIKCIOĞLU, Erhan SARAÇOĞLU, Ertan VURUŞKAN

Effect of Statin Therapyin Tpe-Interval and Tpe/QTc Ratio in Patients with Familial Hypercholesterolemia

Objective: Studies have shown that hypercholesterolemia can induce ventricular vulnerability to fibrillation, and statin therapy exerts antiarrhythmic effects.In the present study, we investigated the relationship between arrhythmogenic substrate and familial hypercholesterolemia(FH) with regard to statin therapy.Methods: We evaluated 46 statin-naive patients (41±12 years) with FH, and 46 healthy subjects (40±8 years) prospectively.Electrocardiography (ECG) of patients were compared before and after 6 months of intensive statin therapy and with controlgroups. The ECG parameters were calculated by two experienced cardiologists who blinded to each other’s findings.Results: There were no significant differences found between groups’ baseline characteristics. Total cholesterol (343±49 mg/dL vs. 161±12 mg/dL; p

PDF

___

1. Liu Y-B, Lee Y-T, Pak H-N, Lin S-F, Fishbein MC, Chen LS, et al. Effects of simvastatin on cardiac neural and electrophysiologic remodeling in rabbits with hypercholesterolemia. Heart Rhythm 2009; 6: 69-75. [Crossref]
2. Tamargo J, Caballero R, Gómez R, Núñez L, Vaquero M, Delpón E. Lipid-lowering therapy with statins, a new approach to antiarrhythmic therapy. Pharmacol Ther 2007; 114: 107-26. [Crossref]
3. Buber J, Goldenberg I, Moss AJ, Wang PJ, McNitt S, Hall WJ, et al. Reduction in life-threatening ventricular tachyarrhythmias in statin-treated patients with nonischemic cardiomyopathy enrolled in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy). J Am Coll Cardiol 2012; 60: 749-55. [Crossref]
4. Xia Y, Liang Y, Kongstad O, Liao Q, Holm M, Olsson B, et al. In vivo validation of the coincidence of the peak and end of the T wave with full repolarization of the epicardium and endocardium in swine. Heart Rhythm 2005; 2: 162-9. [Crossref]
5. Kongstad O, Xia Y, Liang Y, Hertervig E, Ljungström E, Olsson B, et al. Epicardial and endocardial dispersion of ventricular repolarization. A study of monophasic action potential mapping in healthy pigs. Scand Cardiovasc J 2005; 39: 342-7. [Crossref]
6. Porthan K, Viitasalo M, Toivonen L, Havulinna AS, Jula A, Tikkanen JT, et al. Predictive value of electrocardiographic T-wave morphology parameters and T-wave peak to T-wave end interval for sudden cardiac death in the general population. Circ Arrhythm Electrophysiol 2013; 6: 690-6. [Crossref]
7. Laurita KR, Girouard SD, Akar FG, Rosenbaum DS. Modulated dispersion explains changes in arrhythmia vulnerability during premature stimulation of the heart. Circulation 1998; 98: 2774-80. [Crossref]
8. Antzelevitch C, Viskin S, Shimizu W, Yan G-X, Kowey P, Zhang L, et al. Does Tpeak-Tend provide an index of transmural dispersion of repolarization? Heart Rhythm 2007; 4: 1114-6. [Crossref]
9. Hovingh GK, Davidson MH, Kastelein JJ, O'connor AM. Diagnosis and treatment of familial hypercholesterolaemia. Eur Heart J 2013; 34: 962-71. [Crossref]
10. Olshausen KV, Witt T, Pop T, Treese N, Bethge K-P, Meyer J. Sudden cardiac death while wearing a Holter monitor. Am J Cardiol 1991; 67: 381-6. [Crossref]
11. Kuo C-S, Munakata K, Reddy CP, Surawicz B. Characteristics and possible mechanism of ventricular arrhythmia dependent on the dispersion of action potential durations. Circulation 1983; 67: 1356-67. [Crossref]
12. Chua KC, Rusinaru C, Reinier K, Uy-Evanado A, Chugh H, Gunson K, et al. Tpeak-to-Tend interval corrected for heart rate: A more precise measure of increased sudden death risk? Heart Rhythm 2016; 13: 2181-5. [Crossref]
13. Panikkath R, Reinier K, Uy-Evanado A, Teodorescu C, Hattenhauer J, Mariani R, et al. Prolonged Tpeak to Tend interval on the resting electrocardiogram is associated with increased risk of sudden cardiac death. Circ Arrhythm Electrophysiol 2011; 4: 441-7. [Crossref]
14. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. Jama 1999; 282: 2340-6. [Crossref]
15. Pyörälä K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes care 1997; 20: 614-20. [Crossref]
16. Tekin A, Tekin G, Sezgin AT, Müderrisoğlu H. Short-and long-term effect of simvastatin therapy on the heterogeneity of cardiac repolarization in diabetic patients. Pharmacol Res 2008; 57: 393-7. [Crossref]
17. De Sutter J, Tavernier R, De Buyzere M, Jordaens L, De Backer G. Lipid lowering drugs and recurrences of life-threatening ventricular arrhythmias in high-risk patients. J Am Coll Cardiol 2000; 36: 766-72. [Crossref]
18. Mitchell LB, Powell JL, Gillis AM, Kehl V, Hallstrom AP, Investigators A. Are lipid-lowering drugs also antiarrhythmic drugs?: an analysis of the antiarrhythmics versus implantable defibrillators (AVID) trial. J Am Coll Cardiol 2003; 42: 81-7. [Crossref]
19. Vyas AK, Guo H, Moss AJ, Olshansky B, McNitt SA, Hall WJ, et al. Reduction in ventricular tachyarrhythmias with statins in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol 2006; 47: 769-73. [Crossref]
20. Vrtovec B, Okrajsek R, Golicnik A, Ferjan M, Starc V, Radovancevic B. Atorvastatin therapy increases heart rate variability, decreases QT variability, and shortens QTc interval duration in patients with advanced chronic heart failure. J Card Fail 2005; 11: 684-90. [Crossref]
21. Liu Y-B, Wu C-C, Lu L-S, Su M-J, Lin C-W, Lin S-F, et al. Sympathetic nerve sprouting, electrical remodeling, and increased vulnerability to ventricular fibrillation in hypercholesterolemic rabbits. Circ Res 2003; 92: 1145-52. [Crossref]
22. Luo T-Y, Wu C-C, Liu Y-B, Fu Y-K, Su M-J. Dietary cholesterol affects sympathetic nerve function in rabbit hearts. J Biomed Sci 2004; 11: 339-45. [Crossref]
23. Pinto JM, Boyden PA. Electrical remodeling in ischemia and infarction. Cardiovasc Res 1999; 42: 284-97. [Crossref]
24. Hevia JC, Antzelevitch C, Bárzaga FT, Sánchez MD, Balea FD, Molina RZ, et al. Tpeak-Tend and Tpeak-Tend dispersion as risk factors for ventricular tachycardia/ventricular fibrillation in patients with the Brugada syndrome. J Am Coll Cardiol 2006; 47: 1828-34. [Crossref]
25. Zareba W, Moss AJ, le Cessie S. Dispersion of ventricular repolarization and arrhythmic cardiac death in coronary artery disease. J Am Coll Cardiol 1994; 74: 550-3. [Crossref]
26. Antzelevitch C. Tpeak-Tend interval as an index of transmural dispersion of repolarization. Eur J Clin Invest 2001; 31: 555-7. [Crossref]
27. Yayla Ç, Yayla ME, Yayla KG, Ilgen U, Akboğa MK, Düzgün N. The assessment of Tp-e interval and Tp-e/QT ratio in patients with systemic sclerosis. Arch Rheumatol 2016; 31: 139-44. [Crossref]
28. Yayla Ç, Bilgin M, Akboğa MK, Gayretli Yayla K, Canpolat U, Dinç Asarcikli L, et al. Evaluation of Tp‐E interval and Tp‐E/QT ratio in patients with aortic stenosis. Ann Noninvasive Electrocardiol 2016; 21: 287-93. [Crossref]
29. Caballero P, Alonso R, Rosado P, Mata N, Fernández-Friera L, Jiménez-Borreguero LJ, et al. Detection of subclinical atherosclerosis in familial hypercholesterolemia using non-invasive imaging modalities. Atherosclerosis 2012; 222: 468-72. [Crossref]
30. Neefjes LA, Gert-Jan R, Alexia R, Nieman K, Galema-Boers AJ, Langendonk JG, et al. Accelerated subclinical coronary atherosclerosis in patients with familial hypercholesterolemia. Atherosclerosis 2011; 219: 721-7. [Crossref]
31. Miname MH, Ribeiro MS, Parga Filho J, Avila LF, Bortolotto LA, Martinez LR, et al. Evaluation of subclinical atherosclerosis by computed tomography coronary angiography and its association with risk factors in familial hypercholesterolemia. Atherosclerosis 2010; 213: 486-91. [Crossref]
32. Saracoglu E, Kılıç S, Vuruşkan E, Düzen I, Çekici Y, Kuzu Z, et al. Prediction of subtle left ventricular systolic dysfunction in homozygous and heterozygous familial hypercholesterolemia: Genetic analyses and speckle tracking echocardiography study. Echocardiography 2018; 35: 1289-99. [Crossref]
33. Kayikcioglu M, Payzin S, Yavuzgil O, Kultursay H, Can LH, Soydan I. Benefits of statin treatment in cardiac syndrome-X. Eur Heart J 2003; 24: 1999-2005. [Crossref]
34. Crouse JR, Raichlen JS, Riley WA, Evans GW, Palmer MK, O'Leary DH, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. Jama 2007; 297: 1344-53. [Crossref]
35. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. Jama 2006; 295: 1556-65. [Crossref]
36. Rodriguez-Granillo GA, Agostoni P, Garcia-Garcia HM, Biondi-Zoccai GG, Mc Fadden E, Amoroso G, et al. Meta-analysis of the studies assessing temporal changes in coronary plaque volume using intravascular ultrasound. Am J Cardiol 2007; 99: 5-10. [Crossref]